phenyl N-(2,4-difluorophenyl)-carbamate | 65141-00-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenyl N-(2,4-difluorophenyl)-carbamate
• 英文别名: phenyl 2,4-difluorophenylcarbamate；phenyl N-(2,4-difluorophenyl)carbamate
• CAS: 65141-00-6
• 化学式: C₁₃H₉F₂NO₂
• mdl: MFCD20042687
• 分子量: 249.217
• InChiKey: PWOHALINKDREHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  苯并[b]噻吩-2(3H)-酮 、 phenyl N-(2,4-difluorophenyl)-carbamate 生成 N-(2,4-Difluorophenyl)-2-oxo-3,2-dihydro-3-benzo[b]thiophenecarboxamide
  参考文献：
  名称：

  Oxothia compounds

  摘要：

  氧硫杂环化合物，特别是具有以下结构的2-氧代-2,3-二氢苯并[b]噻吩化合物：其中Ph代表可选地取代的1,2-苯基自由基，X代表氧或硫，R.sub.1代表通过碳原子键合的有机基团，R.sub.2表示氢或具有脂肪特性的可选取代的烃基团，以及它们的盐可用作外周镇痛剂和/或抗炎尿酸排泄剂和/或溶血药。

  公开号：

  US04260779A1
• 作为产物：
  描述：

  2,4-二氟苯胺 、 氯甲酸苯酯 在 three 、 水 、 Sodium sulfate-III 、 正己烷 作用下， 以 甲苯 为溶剂， 反应 0.25h， 以to give 1.73 g of the desired product as pale tan crystals in 93% yield, mp 82°-84° C.的产率得到phenyl N-(2,4-difluorophenyl)-carbamate
  参考文献：
  名称：

  Antiatherosclerotic ureas and thioureas

  摘要：

  本发明涉及尿素和硫脲，其可以用以下公式表示：##STR1## 其中X表示至少选择自下列组中的一个取代基：(C.sub.1-C.sub.4)烷基、(C.sub.1-C.sub.4)烯基、(C.sub.1-C.sub.4)炔基、苯氧基、巯基、氨基、(C.sub.1-C.sub.4)烷基氨基、二-(C.sub.1-C.sub.4)烷基氨基、卤素、三卤甲基、(C.sub.1-C.sub.4)酰基、苯甲酰基、(C.sub.1-C.sub.4)酰胺基、卤代乙酰胺基、硝基、氰基、羧基、(C.sub.1-C.sub.4)羧基烷氧基、氨基甲酰基、磺酰胺基、亚甲二氧基、苯基、邻苯二亚基、甲苯基、苯甲基、卤代苯甲基、甲基苯甲基；Y选择自氧和硫的组中；R.sub.1和R.sub.2不同且独立地选择自下列组中：(C.sub.4-C.sub.12)烷基、(C.sub.4-C.sub.12)烯基、(C.sub.4-C.sub.12)炔基、(C.sub.4-C.sub.12)环烷基烷基、(C.sub.7-C.sub.14)芳基烷基和(C.sub.7-C.sub.14)芳基烷基，其中芳环承载至少一个自下列组中选择的取代基：(C.sub.1-C.sub.10)烷基、(C.sub.1-C.sub.10)烷氧基、苯氧基、苄氧基、亚甲二氧基、(C.sub.1-C.sub.4)烷基硫、苯基、卤素、三卤甲基、金刚烷基、(C.sub.1-C.sub.4)羧基烷氧基和硝基。

  公开号：

  US05003106A1

文献信息

• Nitrogen-containing aromatic derivatives
  申请人：——

  公开号：US20040053908A1

  公开（公告）日：2004-03-18

  Compounds represented by the following general formula: 1 [wherein A g is an optionally substituted 5- to 14-membered heterocyclic group, etc.; X g is —O—, —S—, etc.; Y g is an optionally substituted C 6 - 14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and T g1 is a group represented by the following general formula: 2 (wherein E g is a single bond or —N(R g2 )—, R g1 and R g2 each independently represent a hydrogen atom, an optionally substituted C 1-6 alkyl group, etc. and Z g represents a C 1-8 alkyl group, a C 3-8 alicyclic hydrocarbon group, a C 6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.

  由以下一般式表示的化合物： 1 [其中 A g 是可选择地取代的5-至14-成员杂环基团，等等；X g 是—O—，—S—，等等；Y g 是可选择地取代的C 6 - 14 芳基团，可选择地取代的5-至14-成员杂环基团，等等；以及 T g1 是由以下一般式表示的基团： 2 [其中 E g 是单键或—N(R g2 )—，R g1 和R g2 各自独立地表示氢原子，可选择地取代的C 1-6 烷基基团，等等，Z g 表示C 1-8 烷基基团，C 3-8 脂环烃基团，C 6-14 芳基团，等等]， 其盐或上述化合物的水合物。
• Antiatherosclerotic ureas and thioureas
  申请人：American Cyanamid Company

  公开号：US04623662A1

  公开（公告）日：1986-11-18

  This invention is concerned with ureas and thioureas which may be represented by the formula: ##STR1## wherein X represents at least one substituent selected from the group consisting of (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkenyl, (C.sub.1 -C.sub.4)alkynyl, phenoxy, mercapto, amino, (C.sub.1 -C.sub.4)alkylamino, di-(C.sub.1 -C.sub.4)alkylamino, halo, trihalomethyl, (C.sub.1 -C.sub.4)alkanoyl), benzoyl, (C.sub.1 -C.sub.4)alkanamido, haloacetamido, nitro, cyano, carboxy, (C.sub.1 -C.sub.4)carboalkoxy, carbamoyl, sulfamyl, methylenedioxy, phenyl, orthophenylene, tolyl, benzyl, halobenzyl, methylbenzyl; Y is selected from the group consisting of oxygen and sulfur; R.sub.1 and R.sub.2 are different and are independently selected from the group consisting of (C.sub.4 -C.sub.12)alkyl, (C.sub.4 -C.sub.12)alkenyl, (C.sub.4 -C.sub.12)alkynyl, (C.sub.4 -C.sub.12)cycloalkylalkyl, (C.sub.7 -C.sub.14)aralkyl, and (C.sub.7 -C.sub.14)aralkyl in which an aromatic ring bears at least one substituent selected from the group consisting of (C.sub.1 -C.sub.10)alkyl, (C.sub.1 -C.sub.10)alkoxy, phenoxy, benzyloxy, methylenedioxy, (C.sub.1 -C.sub.14)alkylthio, phenyl, halo, trihalomethyl, adamantyl, (C.sub.1 -C.sub.4)carboalkoxy, and nitro.

  这项发明涉及脲和硫脲，可以用以下公式表示：##STR1##其中X代表至少一个取自（C.sub.1 -C.sub.4）烷基，（C.sub.1 -C.sub.4）烯基，（C.sub.1 -C.sub.4）炔基，苯氧基，巯基，氨基，（C.sub.1 -C.sub.4）烷基氨基，二（C.sub.1 -C.sub.4）烷基氨基，卤素，三卤甲基，（C.sub.1 -C.sub.4）烷酰基，苯甲酰基，（C.sub.1 -C.sub.4）烷酰胺基，卤代乙酰胺基，硝基，氰基，羧基，（C.sub.1 -C.sub.4）羧基氧基，氨基甲酰基，磺酰胺基，亚甲二氧基，苯基，邻苯二亚基，甲苯基，苄基，卤苄基，甲基苄基等基团中的至少一个取代基；Y选自氧和硫；R.sub.1和R.sub.2不同且独立选择自（C.sub.4 -C.sub.12）烷基，（C.sub.4 -C.sub.12）烯基，（C.sub.4 -C.sub.12）炔基，（C.sub.4 -C.sub.12）环烷烷基，（C.sub.7 -C.sub.14）芳基烷基和（C.sub.7 -C.sub.14）芳基烷基，其中芳环上至少一个取自（C.sub.1 -C.sub.10）烷基，（C.sub.1 -C.sub.10）烷氧基，苯氧基，苄氧基，亚甲二
• 9-aminoacridine derivatives and process for the preparation thereof
  申请人：Samjin Pharmaceutical Co., Ltd.

  公开号：US20020111491A1

  公开（公告）日：2002-08-15

  The present invention relates to new 9-aminoacridine derivatives of general formula (I), wherein A is hydrogen or (II) (wherein X is oxygen or sulfur, R 1 , R 2 , R 3 , R 4 and R 5 are independently hydrogen, halogen, nitro, amino, hydroxy, C 1 -C 4 lower alkylhydroxy, C 1 -C 4 lower alkylamino, C 1 -C 8 alkyl, C 1 -C 4 lower alkoxy or C 1 -C 4 lower alkyloxycarbonyl and m and n are independently an integer of 0, 1 or 2), R 6 , R 7 , R 8 and R 9 are independently C 1 -C 8 alkyl or C 1 -C 4 lower alkoxy, and Y is hydrogen, amino, -N═CHR′(wherein R′ is hydrogen, benzyl, C 1 -C 8 alkyl or C 1 -C 6 lower alkylamino), (III) (wherein R″ is hydrogen, benzyl, C 1 -C 8 alkyl or C 1 -C 6 lower alkylamino, and R′″ is hydrogen, benzyl, C 1 -C 8 alkyl or amino protecting group) or (IV) (wherein, X is as defined above, R 1 ′, R 2 ′, R 3 ′, R 4 ′ and R 5 ′ are independently hydrogen, halogen, nitro, amino, hydroxy, C 1 -C 4 lower alkylhydroxy, C 1 -C 4 lower alkylamino, C 1 -C 8 alkyl, C 1 -C 4 lower alkoxy or C 1 -C 4 lower alkylcarboxy, and q and r are independently an integer of 0, 1 or 2) or its pharmaceutically acceptable salt, and process for the preparation thereof.

  本发明涉及通式（I）的新9-氨基蒽衍生物，其中A为氢或（II）（其中X为氧或硫，R1、R2、R3、R4和R5独立地为氢、卤素、硝基、氨基、羟基、C1-C4较低烷基羟基、C1-C4较低烷基氨基、C1-C8烷基、C1-C4较低烷氧基或C1-C4较低烷氧羰基，m和n独立地为0、1或2的整数），R6、R7、R8和R9独立地为C1-C8烷基或C1-C4较低烷氧基，Y为氢、氨基、-N═CHR′（其中R′为氢、苄基、C1-C8烷基或C1-C6较低烷基氨基）、（III）（其中R″为氢、苄基、C1-C8烷基或C1-C6较低烷基氨基，R′″为氢、苄基、C1-C8烷基或氨基保护基）或（IV）（其中，X如上定义，R1′、R2′、R3′、R4′和R5′独立地为氢、卤素、硝基、氨基、羟基、C1-C4较低烷基羟基、C1-C4较低烷基氨基、C1-C8烷基、C1-C4较低烷氧基或C1-C4较低烷基羧基，q和r独立地为0、1或2）或其药学上可接受的盐，以及其制备方法。
• Production of Di or tri-azolyl substituted 5-keto azole compounds
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05466820A1

  公开（公告）日：1995-11-14

  An azole compound represented by the formula (I): ##STR1## wherein Ar is a substituted phenyl group; R.sup.1 and R.sup.2 independently are a hydrogen atom or a lower alkyl group, or R.sup.1 and R.sup.2 may combine together to form a lower alkylene group; R.sup.3 is a group bonded through a carbon atom; R.sup.4 is a hydrogen atom or an acyl group; X is a nitrogen atom or a methine group; and Y and Z independently are a nitrogen atom or a methine group which may optionally be substituted with a lower alkyl group, or a salt thereof, which is useful for prevention and therapy of fungal infections of mammals as antifungal agent.

  一种以式子（I）表示的唑类化合物：##STR1## 其中Ar是一个取代的苯基；R.sup.1和R.sup.2分别是氢原子或较低的烷基基团，或R.sup.1和R.sup.2可以结合形成较低的烷基烷基基团；R.sup.3是通过碳原子连接的基团；R.sup.4是氢原子或酰基基团；X是氮原子或甲基基团；Y和Z分别是氮原子或甲基基团，可以选择性地用较低的烷基基团取代，或其盐，用作哺乳动物真菌感染的预防和治疗的抗真菌剂。
• Nitrogen-Containing Aromatic Derivatives
  申请人：Funahashi Yasuhiro

  公开号：US20100197911A1

  公开（公告）日：2010-08-05

  Compounds represented by the following general formula: [wherein A g is an optionally substituted 5- to 14-membered heterocyclic group, etc.; X g is —O—, —S—, etc.; Y g is an optionally substituted C 6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and T g1 is a group represented by the following general formula: (wherein E g is a single bond or —N(R g2 )—, R g1 and R g2 each independently represent a hydrogen atom, an optionally substituted C 1-6 alkyl group, etc. and Z g represents a C 1-8 alkyl group, a C 3-8 alicyclic hydrocarbon group, a C 6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.

  以下是由下列通式表示的化合物：[其中Ag是可选取代的5-至14-成员杂环基团等；Xg是-O-，-S-等；Yg是可选取代的C6-14芳基团，可选取代的5-至14-成员杂环基团等；Tg1是由下列通式表示的基团：（其中Eg是单键或-N（Rg2）-，Rg1和Rg2各自独立地表示氢原子，可选取代的C1-6烷基团等；Zg表示C1-8烷基团，C3-8萜环碳氢基团，C6-14芳基团等）]，其盐或上述化合物的水合物。